Open Access
CC BY 4.0 · Pharmaceutical Fronts 2023; 05(01): e31-e37
DOI: 10.1055/s-0043-1764464
Original Article

Development of a New Process for Tulobuterol Hydrochloride

Autoren

  • Chuan-Jun Wu#

    1   Engineering Research Center for Improvement and Industrialization of Pharmaceutical Processes, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
  • Peng Peng#

    2   Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Zhejiang, People's Republic of China
  • Lin-Tao Xia

    1   Engineering Research Center for Improvement and Industrialization of Pharmaceutical Processes, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
  • Xu Liu

    1   Engineering Research Center for Improvement and Industrialization of Pharmaceutical Processes, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
  • Cai-Xia Yu

    3   College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, People's Republic of China
  • Zhi-Bo Zheng

    2   Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Zhejiang, People's Republic of China
  • Chuan-Meng Zhao

    1   Engineering Research Center for Improvement and Industrialization of Pharmaceutical Processes, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
  • Fu-Li Zhang

    1   Engineering Research Center for Improvement and Industrialization of Pharmaceutical Processes, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China

Funding We are grateful to the China State Institute of Pharmaceutical Industry (CSIPI) and the Engineering Research Center for Improvement and Industrialization of Pharmaceutical Processes for the financial support. The work was also supported by Disha Pharmaceutical Group of China (Grant No. 2022CXGC020504).

Abstract

Tulobuterol is a selective β2-adrenoceptor agonist and has been widely utilized as a therapeutic agent for the treatment of asthma. Synthesis of tulobuterol has achieved many important progresses over the past decades and has gradually become one of the research hotspots in organic chemistry. This study aimed to explore a novel synthesis route to synthesize tulobuterol hydrochloride (1), an active ingredient of Chlobamolie Hydrochloride Tablets. In the study, 1 was obtained from the cost-effective, commercially available 2-chloroacetophenone through the key steps including the reactions of bromination, NaBH4 reduction, and amination. Process-related impurities were also investigated. 1 was obtained with excellent purity (99.96%) in 53% overall yield without the need for chromatographic purification. The developed method is green, facile, and cost-effective; thus, it is suitable for the industrial-scale production of 1.

# These two authors contributed equally to this work and should be considered co-first authors.


Supporting Information

1H NMR and 13C NMR spectra of compounds 3, 1, 6, 7, 8, 9, 10, and 11, as well as HPLC results for the purities of compounds 3 and 1, are included in the Supporting Information ([Figs. S1]–[S18] [online only]).




Publikationsverlauf

Eingereicht: 07. Dezember 2022

Angenommen: 15. Februar 2023

Artikel online veröffentlicht:
16. März 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany